PLUS THERAPEUTICS, INC.PSTVEarnings & Financial Report
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
Revenue
$1.5M
Gross Profit
N/A
Operating Profit
$-3.8M
Net Profit
$-2.9M
Gross Margin
N/A
Operating Margin
-260.9%
Net Margin
-197.4%
YoY Growth
N/A
EPS
$-0.37
PLUS THERAPEUTICS, INC. Q3 FY2024 Financial Summary
PLUS THERAPEUTICS, INC. reported revenue of $1.5M for Q3 FY2024, with a net profit of $-2.9M (up 10.7% YoY) (-197.4% margin).
Key Financial Metrics
| Total Revenue | $1.5M |
|---|---|
| Net Profit | $-2.9M |
| Gross Margin | N/A |
| Operating Margin | -260.9% |
| Report Period | Q3 FY2024 |
PLUS THERAPEUTICS, INC. Annual Revenue by Year
PLUS THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $5.2M |
| 2024 | $5.8M |
PLUS THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
PLUS THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.4M | -3.2% | $-5.7M | -417.9% |
| Q3 FY2025 | $1.4M | -4.1% | $-4.4M | -316.6% |
| Q2 FY2025 | $1.4M | +8.7% | $5.2M | 370.6% |
| Q1 FY2025 | $1.1M | -36.9% | $-17.4M | -1643.2% |
| Q4 FY2024 | $1.4M | — | $-3.9M | -276.4% |
| Q3 FY2024 | $1.5M | — | $-2.9M | -197.4% |
| Q2 FY2024 | $1.3M | — | $-2.9M | -229.9% |
| Q1 FY2024 | $1.7M | — | $-3.3M | -194.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.3M | $1.5M | $1.4M | $1.1M | $1.4M | $1.4M | $1.4M |
| YoY Growth | N/A | N/A | N/A | N/A | -36.9% | 8.7% | -4.1% | -3.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $5.6M | $11.2M | $7.0M | $6.6M | $12.1M | $10.3M | $18.7M | $16.3M |
| Liabilities | $10.5M | $18.8M | $12.2M | $15.6M | $35.7M | $7.3M | $13.6M | $12.3M |
| Equity | $-4.8M | $-7.6M | $-5.2M | $-8.9M | $-23.6M | $3.0M | $5.1M | $4.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.5M | $-1.1M | $-3.7M | $-1.2M | $-6.2M | $-5.8M | $-2.5M | $-6.3M |